Cure8 research brief
If validated, metabolite patterns could help predict which children will reach remission on vedolizumab, potentially guiding treatment choices and avoiding ineffective therapy.
Pediatric IBD clinicians; researchers studying biomarkers or vedolizumab; parents/caregivers of children starting vedolizumab.
This multicenter prospective study (VedoKids) tested whether serum metabolite profiles predict clinical remission after vedolizumab in children with IBD.
Researchers measured metabolites at baseline, week 14, and week 30 and used machine-learning models (random forest with feature selection) combining clinical and metabolomic data to predict remission at the next visit. The study included 138 children (mean age ~13.6 years) with Crohn’s disease or ulcerative colitis.
Models showed good-to-strong performance (AUROC ranged ~0.72–0.92 depending on disease and timepoint). Specific metabolites (for CD: PC ae C36:4, citric acid, malic acid; for UC: LysoPC a C26:1, picolinic acid, serotonin) were among top predictive features.
This is an abstract-level report of a prospective cohort study; it describes promising biomarker associations but does not establish clinical utility or that metabolite testing is ready for routine care.
Results are from the study abstract and report predictive-model accuracy (AUROC) and candidate metabolites. This does not yet equate to a clinically available test; independent validation and implementation studies are required.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Patients, families, and clinicians may care because the study shows pediatric-onset IBD is more often Crohn's and that children begin advanced therapies earlier than adults. The adult persistence data for vedolizumab and...
Vedolizumab blood levels can vary with disease activity; a model that links intestinal α4β7 expression to drug exposure helps explain why some patients have lower drug levels and may need different dosing. This could...
People with IBD and their clinicians want ways to predict which advanced therapy will work best. This review summarizes current evidence and shows that, despite many studies, no biomarker is reliably ready for routine...
